Sugi Predict

Sugi Predict / Targets / CDC25A

CDC25A

M-phase inducer phosphatase 1 · P30304 · CDC25A on Sugi Atlas →

52,134 patent compounds predicted against CDC25A, 33,237 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL130160 SCHEMBL130160 0.41 9/20
SCHEMBL134428 SCHEMBL134428 0.55 8/20
SCHEMBL179749 SCHEMBL179749 0.32 8/20
SCHEMBL82554 SCHEMBL82554 0.69 7/20
SCHEMBL170030 SCHEMBL170030 0.42 6/20
SCHEMBL187581 SCHEMBL187581 0.39 6/20
SCHEMBL45540 SCHEMBL45540 0.34 6/20
SCHEMBL254004 SCHEMBL254004 0.70 5/20
SCHEMBL135273 SCHEMBL135273 0.61 5/20
SCHEMBL64776 SCHEMBL64776 0.58 5/20
Ubiquinone Qo Ubiquinone Qo (SCHEMBL49420) 0.45 5/20
SCHEMBL106015 SCHEMBL106015 0.77 4/20
Menadione Menadione (SCHEMBL207465) 0.72 4/20
SCHEMBL260558 SCHEMBL260558 0.71 4/20
SCHEMBL141358 SCHEMBL141358 0.66 4/20
SCHEMBL105206 SCHEMBL105206 0.64 4/20
SCHEMBL104504 SCHEMBL104504 0.63 4/20
SCHEMBL105651 SCHEMBL105651 0.57 4/20
SCHEMBL112795 SCHEMBL112795 0.56 4/20
SCHEMBL228422 SCHEMBL228422 0.56 4/20

Clinical trials — most relevant to CDC25A by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Clinical and Pharmacoeconomic Assessment of CDK4/6 Inhibitors for Treatment of Breast Cancer in Egypt PHASE4COMPLETED
Effect of Silymarin in Metastatic Colorectal Cancer Patients PHASE3UNKNOWN
A Study of BEBT-209 Plus Chemotherapy in Patients With Locally Advanced or Metastatic Triple-Negative Breast Cancer PHASE2/PHASE3NOT_YET_RECRUITING
A Study of Azenosertib (ZN-c3) Versus Investigator's Choice Chemotherapy in Subjects With Platinum-Resistant High-Grade Serous Ovarian, Primary Peritoneal, or Fallopian Tube Cancers Positive for Cyclin E1 Protein Expression PHASE3RECRUITING
TQB3616 Capsules Combined With Abiraterone Acetate Plus Prednisone in Metastatic Castration-Resistant Prostate Cancer PHASE2UNKNOWN
Clinical Trial to Determinate Dose, Security and Efficacy or Lenalidomide and Rituximab (LR)-ESHAP in Patients With Diffuse Large B-cell Lymphoma PHASE1/PHASE2COMPLETED
Clinical Study of EBV-LMP1 Targeted DNAzyme to Treat Nasopharyngeal Carcinoma PHASE1/PHASE2COMPLETED
Efficacy Study Of P276-00 In Subjects Of Malignant Melanoma Positive For Cyclin D1 Expression PHASE2COMPLETED
Phase II, Single-arm Study of AZD1775 Monotherapy in Relapsed Small Cell Lung Cancer Patients PHASE2COMPLETED
Everolimus for Children With Recurrent or Progressive Ependymoma PHASE2COMPLETED
Rapamycin for Immunosuppression and B Cell Modulation Post Stem Cell Transplant for Acute Lymphoblastic Leukemia (ALL) PHASE2COMPLETED
Phase II Study of Sorafenib + Carboplatin and Docetaxel in First Line Treatment of Stage IIIB/IV NSCLC PHASE2COMPLETED
Everolimus in Treating Patients With Relapsed or Refractory Multiple Myeloma PHASE2COMPLETED
Study With Wee-1 Inhibitor AZD1775 (MK-1775) and Carboplatin to Treat p53 Mutated Refractory and Resistant Ovarian Cancer PHASE2COMPLETED
Lapatinib Ditosylate in Treating Patients With Unresectable Liver or Biliary Tract Cancer PHASE2COMPLETED
Adavosertib and Irinotecan Hydrochloride in Treating Younger Patients With Relapsed or Refractory Solid Tumors PHASE1/PHASE2COMPLETED
Bortezomib After Combination Chemotherapy, Rituximab, and an Autologous Stem Cell Transplant in Treating Patients With Mantle Cell Lymphoma PHASE2COMPLETED
AZD1775 for Advanced Solid Tumors PHASE1COMPLETED
Phase I Study of Oral BAY 1217389 in Combination With Intravenous Paclitaxel PHASE1COMPLETED
Veliparib (ABT-888), an Oral PARP Inhibitor, and VX-970, an ATR Inhibitor, in Combination With Cisplatin in People With Refractory Solid Tumors PHASE1COMPLETED
Combination Chemotherapy in Treating Patients With Refractory or Recurrent Solid Tumors PHASE1COMPLETED
PS-341 and Radiation to Treat Advanced Cancer of the Head and Neck PHASE1COMPLETED
Study of ABT-751 in Patients With Refractory Hematologic Malignancies PHASE1COMPLETED
Wee1 Kinase Inhibitor AZD1775 and Combination Chemotherapy in Treating Children, Adolescents and Young Adults With Relapsed or Refractory Acute Myeloid Leukemia PHASE1WITHDRAWN
Role of ADA SNPs in Subjects With Relapsing Multiple Sclerosis (RMS) nanUNKNOWN
A Clinical Evaluation of Everolimus Eluting Coronary Stents in the Treatment of Patients With ST-segment Elevation Myocardial Infarction: EXAMINATION Study nanCOMPLETED
Diagnostic and Prognostic Value of PTEN Expression in Functional and Pathological Endometrial Biopsies nanCOMPLETED
CircularRNA-microRNA-mRNA Regulatory Axis in IVF nanNOT_YET_RECRUITING
Study of Tissue and Blood Samples From Patients With Low-Grade Glioma nanCOMPLETED
Cyclin-dependent Kinase Inhibitor 2A (Placental Senescence Marker) on Labor-related Signals nanUNKNOWN

Related proteins — ESM-2 sequence neighbours (a CDC25A binder may also engage these)

ProteinNameSimilarity
A7MBD1 — 1.000 A7MBD1 →
P48964 — 1.000 P48964 →
P48966 — 1.000 P48966 →
P48965 — 1.000 P48965 →
CDC25B M-phase inducer phosphatase 2 0.998 landscape →
P30306 — 0.994 P30306 →
P30310 — 0.992 P30310 →
Q29029 — 0.991 Q29029 →
CDC25C M-phase inducer phosphatase 3 0.989 landscape →
A5D7P0 — 0.989 A5D7P0 →
Q9BY84 — 0.989 Q9BY84 →
P30309 — 0.987 P30309 →
P30308 — 0.986 P30308 →
P30311 — 0.985 P30311 →
P48968 — 0.982 P48968 →
P24793 — 0.982 P24793 →
E1BTE1 — 0.980 E1BTE1 →
P48967 — 0.980 P48967 →
Q5QJC2 — 0.980 Q5QJC2 →
D2HHP1 — 0.979 D2HHP1 →
Q9R207 — 0.979 Q9R207 →
Q6P1H6 — 0.979 Q6P1H6 →
Q1LWL8 — 0.979 Q1LWL8 →
E2RSS3 — 0.978 E2RSS3 →
Q28FA8 — 0.978 Q28FA8 →
Q8TEW8 — 0.978 Q8TEW8 →
Q66JT0 — 0.977 Q66JT0 →
A4QNA8 — 0.977 A4QNA8 →
Q6A098 — 0.977 Q6A098 →
Q9JIL9 — 0.977 Q9JIL9 →